Background: Anaerobic bacterial resistance trends may vary across regions or institutions. Regional susceptibility patterns are pivotal in the empirical treatment of anaerobic infections. We determined the antimicrobial resistance patterns of clinically important anaerobic bacteria, including recently named or renamed anaerobes.
INTRODUCTION
The prevalence of antibiotic resistance in anaerobes is increasing, which impacts both antibiotic treatment and patient mortality [1] . Regional susceptibility patterns are pivotal in the empirical treatment of anaerobic infections. As the resistance trends of anaerobic bacteria may vary greatly, across regions or institutions [2] [3] [4] , antimicrobial susceptibility tests (ASTs) should be performed to assist with empirical antimicrobial treatment of anaerobic infections.
METHODS

Bacterial isolates
A total of 521 non-duplicated clinical anaerobic bacteria isolates were collected from a tertiary-care hospital (Severance Hospital, Seoul, Korea) between 2014 and 2016. Anaerobes were isolated from blood, body fluids, and abscess specimens. Each isolate was identified by conventional methods, Bruker biotyper mass spectrometry (Bruker Daltonics, Leipzig, Germany), or VI-TEK matrix-assisted laser desorption ionization time-of-flight mass spectrometry (bioMérieux, Marcy-l'Étoile, France).
We tested a total of 230 gram-negative isolates, including 60 Bacteroides fragilis, 68 non-fragilis Bacteroides spp., 29 Parabacteroides spp., 33 Prevotella spp., 19 Fusobacterium spp., 10 other anaerobic GNB, and 11 Veillonella spp. Non-fragilis Bacteroides isolates were divided into two groups as follows: Group I included B. thetaiotaomicron, B. caccae, B. uniformis, B. vulgatus, and B. ovatus; Group II were recently classified, renamed, or infrequently isolated including B. intestinalis, B. nordii, B. pyogenes, B. stercoris, B. salyersiae, and B. cellulosilyticus. A total of 291 gram-positive isolates were tested, including 31 Finegoldia magna, 29 Parvimonas micra, 14 other grampositive cocci (GPC), 15 Clostridioides difficile, 27 Clostridium spp., 34 Actinomyces odontolyticus, 23 Actinomyces spp., 18 Bifidobacterium spp., 38 Eggerthella lenta, 36 Lactobacillus spp., and 26 other gram-positive bacilli.
ASTs
ASTs were conducted using the agar dilution method, and minimum inhibitory concentrations (MICs) were interpreted according to the CLSI guidelines [5, 19] . The medium used was Brucella agar (Becton Dickinson, Cockeysville, MD, USA) supplemented with 5 µg/mL hemin, 1 µg/mL vitamin K1, and 5% laked sheep blood. The following antimicrobials were tested: penicillin (Sigma Aldrich, Yongin, Korea), piperacillin-tazobactam (Yuhan, Seoul, Korea), cefoxitin (Merck Sharp & Dohme, West Point, PA, USA), cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), imipenem and metronidazole (Choongwae, Seoul, Korea), clindamycin (Korea Upjohn, Seoul, Korea), meropenem (Sumitomo, Tokyo, Japan), moxifloxacin (Bayer Korea, Seoul, Korea), chloramphenicol (Chong Kun Dang, Seoul, Korea), and tetracycline (Sigma Aldrich). For the piperacillin and tazobactam combination, a constant concentration of tazobactam (4 µg/mL) was added. An inoculum of 10 5 colony forming units (CFUs) was applied with a Steers replicator (Craft Machine Inc., Woodline, PA, USA), and the plates were incubated in an anaerobic chamber (Forma Scientific, Marietta, OH, USA) for 48 hours at 37°C. Quality control was tested with the following two organisms: B. fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741. Double-disk potentiation tests (DPTs) with dipicolinic acid were carried out on Brucella agar to screen for carbapenemase-producing B. fragilis group isolates [20] .
RESULTS
Anaerobic gram-negative isolates
Most of the gram-negative isolates tested were susceptible to piperacillin-tazobactam, imipenem, and meropenem, as their resistance rates to these three antimicrobials were < 7% (Table 1) . Low frequencies of resistance to chloramphenicol and metronidazole were observed for most of the anaerobic gram-negative bacterial isolates tested. High rates of resistance to penicillin (98-100%), cefotetan (12-71%), and clindamycin (38-69%) were noted for the B. fragilis group isolates. The resistance of B. fragilis isolates to cefotetan was 12%; however, the non-fragilis Bacteroides Group II isolates showed high resistance to cefotetan (71%). Furthermore, Parabacteroides spp. (including P. distasonis), reclassified from the genus Bacteroides, showed very high resistance to cefotetan (95-100%). Table 1 . Continued gilis Bacteroides group I and II isolates to moxifloxacin was 20% and 16%, respectively. Overall, Parabacteroides spp. exhibited higher resistance rates relative to B. fragilis spp., especially for clindamycin (79%) and moxifloxacin (24%). Bacteroides fragilis exhibited imipenem and meropenem-resistance rates of 5%. Non-fragilis Bacteroides Group I showed resistance to only imipenem (2%), while non-fragilis Bacteroides Group II showed resistance to only meropenem (14%). The meropenem MIC required to decrease growth by 90% (MIC90 = 16 µg/mL) for nonfragilis Bacteroides Group II was higher than that for B. fragilis and non-fragilis Bacteroides Group I (MIC90 = 2 µg/mL). Four carbapenem-non-susceptible B. fragilis isolates showed positive results on DPTs, whereas eight carbapenem-non-susceptible non-fragilis Bacteroides isolates (including B. thetaiotaomicron, B. intestinalis, B. nordii, P. distasonis, and P. merdae) showed negative results.
Overall, Prevotella and Fusobacterium isolates were more susceptible to antimicrobial agents than B. fragilis group isolates. Interestingly, one Prevotella spp. isolate was resistant to metronidazole (3%). The other anaerobic GNB were susceptible to most of the antibiotics tested. However, all Leptotrichia isolates were resistant to moxifloxacin (MIC = 8-16 µg/mL). Megamonas spp. and Sutterella wadsworthensis were resistant to piperacillin-tazobactam (MIC ≥ 128 µg/mL), and three Veillonella isolates (27%) were resistant to metronidazole.
Anaerobic gram-positive isolates
A total of 74 anaerobic GPC, including 31 Finegoldia magna and 29 Parvimonas micra, exhibited various resistance rates to moxifloxacin (6-48%), clindamycin (3-43%), and tetracycline (6-86%). Overall, F. magna isolates were more susceptible than other GPC isolates, with a resistance rate < 6% to all antimicrobials tested (Table 1 ). The resistance rate of the other GPC isolates to penicillin was 36%, with all species identified as Peptoniphilus.
C. difficile showed high resistance to penicillin (100%), cefoxitin (100%), imipenem (93%), and moxifloxacin (53%). All nonodontolyticus Actinomyces and Lactobacillus isolates and 65% of Actinomyces odontolyticus isolates were resistant to metronidazole. All non-odontolyticus Actinomyces isolates were susceptible to the other antimicrobial agents tested, except for clindamycin (22% resistance) and tetracycline (22% resistance). E. lenta demonstrated high resistance rates to penicillin (47%), cefotetan (95%), tetracycline (61%), and moxifloxacin (32%). Other GPB, such as Actinotignum, Alloscardovia, Bulleidia, Collinsella, Flavonifractor, and Slackia, were generally susceptible to all agents tested, except for metronidazole. [21] . The resistance to moxifloxacin among non-fragilis Bacteroides group species has not increased; the rates have ranged from 18% in 2007-2008 to 16% in 2014-2016 [7] . This may reflect the fact that the B. fragilis group includes former members of the group previously reclassified as Parabacteroides spp. [7] . Parabacteroides spp. had a higher resistance rate to clindamycin and a lower resistance rate to moxifloxacin compared with isolates in the USA (50% and 44%, respectively) [21] .
We observed that non-fragilis Bacteroides Group II had higher resistance rates to meropenem than imipenem, while non-fragilis Bacteroides Group I demonstrated the opposite pattern. Such patterns have been previously reported by Sóki et al. [22] ; however, they did not include the carbapenem resistance patterns of non-fragilis Bacteroides Group II.
Prevotella spp. were highly susceptible to most antimicrobials except penicillin and clindamycin. The resistance rates to clindamycin remained high, at 45%, for Prevotella spp., compared with 50% in 2007-2008 [7] . Only one Prevotella spp. isolate was resistant to metronidazole. This represents an even lower rate of resistance than that reported in Greece (8%) [23] . The Veillonella resistance rate to metronidazole was 27%, higher than that reported in the USA (11%) [4] .
The anaerobic GPC isolates exhibited various rates of resistance to penicillin, clindamycin, and metronidazole [2] . However, the resistance rate of GPC to clindamycin, moxifloxacin, and tetracycline varied across species. The resistance of C. difficile to imipenem has rapidly increased over the past years, from 8% in 2007-2008 to 93% in 2014-2016 [7] . There is a general assumption that resistance varies with ribotype; Lee et al. [24] showed that ribotypes 017 and 018 have high MICs for moxifloxacin and imipenem, compared with ribotype 001. Metronidazole-resistant isolates were common among Actinomyces and Lactobacillus spp. A study in Argentina showed that all Actinomyces spp. were susceptible to penicillin, and 21.2% were resistant to clindamycin [25] . E. lenta has been commonly associated with gastrointestinal infections; its overall mortality is significant, ranging from 36% to 48% [26, 27] . The E. lenta resistance rates we observed were much higher than those in Australia (0% for penicillin and 12% for moxifloxacin) [26] .
The limitations of this study were the small number of renamed and reclassified bacteria and bacterial isolates collected. Further, it was a single-center, retrospective study.
In conclusion, piperacillin-tazobactam, cefoxitin, and carbapenems were β-lactam agents highly active against most of the anaerobic bacteria we tested. However, recently renamed non-fragilis Bacteroides group isolates showed resistance to meropenem (14%). These data suggest the importance of ongoing surveillance to provide clinically relevant information to clinicians for the empirical management of infections caused by anaerobic organisms. Continuous monitoring is necessary to detect changes in antimicrobial resistance patterns.
Authors' Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.
